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Abstract
Background: Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®)
often experience injection-site reactions and injection-site pain, which together with other side-effects (such as flu-like
symptoms) result in suboptimal treatment compliance/adherence. The EXCHANGE study evaluated patient satisfaction
with IFN β-1b treatment, administered using ExtaviPro™ 30G, a new auto-injector, in a real-world setting.
Methods: This 26-week, open-label, prospective, non-interventional, observational, multi-country multi-centre study
enrolled patients with MS who had been treated with IFN β-1b or other disease-modifying therapies with a self-
administered auto-injector for ≥3 months and who were planned to switch to IFN β-1b treatment administered using
ExtaviPro™ 30G as part of routine clinical care. Patient-reported outcomes included overall patient satisfaction (primary
outcome) and satisfaction associated with treatment effectiveness, convenience and side-effects, assessed using
Treatment Satisfaction Questionnaire for Medication (TSQM)-14. The changes in TSQM scores from baseline to Week 26
were reported. All data were analysed using SAS statistical software (version 9.4).
Results: Of the 336 patients enrolled, 324 were included in the analysis. At baseline, mean ± standard deviation (SD)
age of patients was 41.8 ± 11.3 years and 68.2% were women. The mean ± SD of MS disease duration was
6.9 ± 6.6 years, and the majority of patients (94.1%) had relapsing-remitting MS. The mean ± SD of TSQM
score for overall patient satisfaction at Week 26 was 75.6 ± 16.46 (baseline, 73.0 ± 17.14; p = 0.0342). The
mean ± SD of TSQM subscale scores for patient satisfaction with effectiveness, side-effects and convenience
were 75.0 ± 18.65 (baseline, 71.6 ± 19.45; p = 0.0356), 88.5 ± 18.98 (baseline, 82.7 ± 22.93; p = 0.0002) and
77.6 ± 16.72 (baseline, 71.1 ± 17.53; p < 0.0001), respectively.
Conclusion: The results from this real-world study suggest that administering IFN β-1b with the new ExtaviPro™
auto-injector significantly improves overall patient satisfaction, including satisfaction associated with effectiveness,
side-effects and convenience in MS patients.
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Background
Multiple sclerosis (MS) is a chronic immune-mediated
disease characterised by inflammation, axonal damage
and demyelination in the central nervous system
(CNS) [1]. Patients experience acute transient exacer-
bations of neurological symptoms (relapses) followed
by periods of clinical stabiliosation during the early
stages of the disease, and eventually worsening of
neurological condition occurs in the form of disability
over a period of time [2]. Currently, ~2.5 million
people globally have MS [3].
Disease-modifying treatments (DMTs) such as inter-
ferons (IFNs; IFN β-1a, IFN β-1b) and glatiramer
acetate are commonly prescribed as first-line therapies
for relapsing forms of MS [4]. IFN β is postulated to
modulate the immune system in MS through several
potential pathways. Among these mechanisms, inhib-
ition of T-cell migration from the periphery into the
CNS and reduction in metalloproteinase activity on
the vascular endothelium that constitutes the blood-
brain barrier may be important [5, 6].
IFNs administered subcutaneously or intramuscu-
larly have been shown to reduce the number and se-
verity of clinical exacerbations, disability worsening,
need for steroid treatment and the number of hospi-
talisations in patients with relapsing-remitting MS
(RRMS) [7–10]. However, patients receiving long-term
subcutaneous IFN β-1b often experience injection-site
reactions and injection-site pain/inflammation, to-
gether with other side-effects, such as flu-like symp-
toms [11, 12], resulting in suboptimal treatment
compliance and adherence in a substantial number of
patients [13, 14].
Injection-site reactions may be related to IFN β-1b
being injected or to the injection itself. Use of an auto-
injector and thinner needle may improve patient
experience and contribute to improving adherence to
treatment. Several auto-injectors are available for most
IFNs to improve treatment satisfaction, mitigate
injection-site reactions and pain concerns associated
with mechanical/manual injectors [15–18].
A new, improved auto-injector system, ExtaviPro™ 30G
(Novartis Pharma AG), has been developed to facilitate
self-administration of IFN β-1b (Extavia®). Compared with
previous ExtaviJect® 30G, the new ExtaviPro™ 30G auto-in-
jector is ergonomically designed to make the device
easier to use and reliable and to reduce injection-site
reactions and pain. The auto-injector facilitates self-
administration of high-dose and high-frequency
subcutaneous injections of IFN β-1b [19]. ExtaviPro™
uses an ultra-thin 30G needle that reduces shaking or
jolting of the auto-injector and facilitates single-
handed use and easy access to difficult-to-reach
injection sites [19]. Collectively, these features can
lead to a better treatment experience and reduced
injection-site reactions and associated pain, which
can, in turn, improve adherence. ExtaviPro™ 30G is
widely available across Europe.
The current non-interventional, real-world study
aimed to evaluate patient and nurse satisfaction with
ExtaviPro™ 30G auto-injector as a new delivery device
for IFN β-1b (Extavia®) in the treatment of MS in the
Europe. The primary objective of the study was to
evaluate overall patient satisfaction with Extavia®
delivered using the new ExtaviPro™ auto-injector. The
secondary objectives included patient-perceived effect-
iveness, convenience and side-effects. Patient toler-
ability to injection-site reactions, treatment adherence
and nurse satisfaction were also evaluated.
Methods
Patient population
Men and women aged ≥18 years who had been
treated with IFN β-1b (Extavia®) or other injectable
first-line DMTs (IFN β-1b [Betaferon®/Betaseron®],
IFN β-1a [Avonex®] or glatiramer acetate [Copaxone®])
for MS using a self-administering auto-injector device
for at least 3 months before the study entry, who
were recommended to switch to IFN β-1b (Extavia®)
administered using new ExtaviPro™ 30G auto-injector
based on the medical need as part of routine clinical care
and in compliance with the local prescribing information,
were included in the study. Patients provided written in-
formed consent prior to their enrolment in the study.
Study design
This was a 26-week, single-arm, open-label, prospective,
observational study, conducted between February 2014
and August 2015 at 74 sites in six countries in Europe:
Bulgaria, Germany, Greece, Italy, Poland and Spain.
At baseline (Day 1), eligible patients were transitioned to
IFN β-1b (Extavia®) self-administered using ExtaviPro™
auto-injector and entered into a 26-week observation
period. Because this was an observational study, all patients
were eligible for the treatment with IFN β-1b (Extavia®),
which was prescribed based on the local prescribing infor-
mation. Data for the study were collected at routine clinical
visits and were recorded by physicians at baseline (Day 1)
and at Weeks 4, 13 and 26, except for Bulgaria where data
were collected only at Week 26 because routine visits took
place every 6 months.
Only patient-reported outcomes were assessed during
the study period; no additional laboratory tests or med-
ical procedures were conducted. If required, the dose
was titrated in accordance with the locally approved pre-
scribing information.
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Assessments
Patient-reported outcomes
Treatment satisfaction The primary endpoint of the
study was overall patient satisfaction with IFN β-1b
(Extavia®) at Week 26, delivered using the new
ExtaviPro™ auto-injector, as assessed by the Treatment
Satisfaction Questionnaire for Medication (TSQM).
The TSQM (version 1.4) is a 14-item, reliable, vali-
dated instrument for assessing patient satisfaction
with medication, providing overall scores on four
scales including ‘global satisfaction’, ‘effectiveness’, ‘side
effects’ and ‘convenience’ [20]. The TSQM was also
available in local languages. Patients were asked to
refer to their prior treatment and auto-injector for as-
sessment of treatment satisfaction at baseline, and for
IFN β-1b (Extavia®) and ExtaviPro™ for all subsequent
assessments.
The secondary endpoints of the study included mean
scores of individual subscales of the TSQM—‘effective-
ness’, ‘side effects’ and ‘convenience’—at Week 26 [20].
Tolerability for ExtaviPro™: Pain and injection-site reactions
The tolerability for IFN β-1b (Extavia®) injected through
ExtaviPro™ auto-injector consisted of injection-site pain
and injection-site reactions at Week 26 and was assessed
using the short-form McGill Pain Questionnaire
(SF-MPQ) [21] and injection-site reaction questionnaire
[22], respectively.
The SF-MPQ comprises 15 descriptors (11 sensory
and 4 affective) rated on an intensity scale as follows:
0 = none, 1 = mild, 2 = moderate or 3 = severe. Three
pain scores were derived from the sum of the intensity
rank values: sensory, affective and total descriptors.
Moreover, the SF-MPQ included the Present Pain
Intensity Index of the standard MPQ and a visual
analogue scale (VAS) [21].
Patients were asked to respond to two questions related
to injection-site reactions in the 4 weeks prior to the
current visit: ‘Do injection-site reactions occur more or
less often now?’ and ‘Do the injection-site reactions cause
more or less discomfort now?’ These questions were
adapted from the Multiple Sclerosis Treatment Concerns
Questionnaire (MSTCQ) [15]. The response was selected
from the five options: much less, somewhat less, about the
same, somewhat more and much more [22].
Adherence
Patient adherence to IFN β-1b (Extavia®) delivered
through ExtaviPro™ auto-injector was assessed by the
Multiple Sclerosis Treatment Adherence Questionnaire
(MSTAQ). The MSTAQ is a 30-item questionnaire
designed to identify factors affecting patient adherence
and barriers to treatment adherence in patients using MS
DMTs. The tool was also designed to predict missed
doses. The MSTAQ has three subscales: barriers
(score 0–39), side-effects (score 0–40) and coping
strategies (score 0–7) [23].
Healthcare provider-reported outcomes
The proportion of patients reporting incidence of injection-
site reactions (specifically pain, swelling, redness, itching or
bruising) was evaluated using a physician-completed
questionnaire for capturing patients’ reports of reactions
over the 4 weeks before the visit [15].
Satisfaction of healthcare providers was evaluated
based on nurses’ acceptance of delivering IFN β-1b
(Extavia®) through ExtaviPro™ auto-injector, which was
assessed using nurse questionnaires. The nurse question-
naires assessed the ease of switching patients to the
ExtaviPro™ 30G auto-injector and the overall satisfaction
with the injector device (2 items: baseline and follow-up
visits). Two questions were asked at baseline visit: ‘How
easy was it for the patient to learn to use the device?’
and ‘How easy is it expected to be for the patient to use
the device?’ Two similar questions were asked during
follow-up visits: ‘Was additional training required?’ and
‘How easy did the patient find it to use the device?’
The response to all questions was selected from the
four options: ‘very difficult’, ‘difficult’, ‘easy’ and ‘very easy’.
The response to the level of additional training required
was selected from the four options: ‘none’, ‘less than half ’,
‘more than half ’ and ‘repeat entire training’.
Safety
Safety assessments included reporting of adverse events
(AEs) and serious AEs (SAEs).
Sample size determination and statistical analysis
Assuming a drop-out rate of 15%, 333 patients were
planned for enrolment to achieve the target sample size of
283 patients. This sample size allows estimation of the
true mean TSQM global satisfaction score within a mar-
gin of error of ±2.6 using a two-sided 95% confidence
interval (CI) based on an estimated standard deviation
(SD) of 22.3 from a historical data.
Treatment satisfaction, tolerability, adherence and
other results for the IFN β-1b (Extavia®) group were
compared between the previous auto-injector (baseline)
and new auto-injector (ExtaviPro™) at Week 26. The
change from baseline in the TSQM Global Satisfaction
subscale score at Week 26 was analysed using a linear
mixed model for repeated measures at 95% CI, with week
as the fixed effect and baseline scores as a continuous
covariate. A 95% CI was constructed using the least
squares mean (i.e. adjusted mean at the overall baseline
mean value) and the within-subject variance obtained
from the linear mixed model. In case of missing data, the
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CI was valid under the assumption that the missing data
have a missing-at-random mechanism.
Tolerability in terms of satisfaction with the side-
effect domain on TSQM subscale, SF-MPQ and the
injection-site reaction questionnaires were also
analysed using a linear mixed model for repeated
measures. The change in MSTAQ scores over time
compared with baseline scores was analysed using a
linear mixed model for repeated measures following
the methodology described above. The treatment
compliance rate over time versus baseline scores was
analysed using the Chi-square test. Compliance was
calculated considering the 2-week period before each
follow-up visit, excluding the baseline visit. Given the
real-world nature of the data, any missing data were
assumed to be missing at random and imputation
methods were not applied to ensure description of
real patient management in clinical practice.
All data analyses were conducted using SAS statistics
software version 9.4 (SAS Institute Inc., Cary, NC) and in
accordance with the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) [24]
guidelines and applicable sections of the Consolidated
Standards of Reporting Trials (CONSORT) guidelines [25].
Ethical and good clinical practice
The study protocol and amendment were reviewed and
approved by the Independent Ethics Committees and
Institutional Review Boards at each centre per local
regulations. All patients provided written informed
consent before study entry. The study was conducted in
compliance with the ethical principles of the Declaration
of Helsinki and the International Conference on
Harmonisation Good Clinical Practice Guidelines [26].
Results
Patient disposition and baseline characteristics
Of the 336 enrolled patients at 74 sites, the majority
were receiving IFNβ-1b (93.5%, n = 314) and the
remaining were receiving other DMTs (6.5%, n = 22) as
a part of their routine care. In total, 324 patients were
included in the final analysis. Twelve patients were ex-
cluded from the analysis: one patient (~4.5%) in the
other DMTs group did not receive any treatment and 11
(3.5%) in the IFNβ-1b (Extavia®) group used ExtaviPro™
before study inclusion.
Demographics and baseline characteristics of patients
are described in Table 1. The overall mean (range) age
of patients was 41.8 (19.0–68.0) years, and 68.2% of all
patients were women. At baseline, most of the patients
(94.1%) had RRMS and the mean duration since diagno-
sis was 6.9 ± 6.59 years; 41.0% of the patients reported
exacerbations during 2 years before study entry, with a
mean ± SD of 1.6 ± 0.79 exacerbations per patient. In
Table 1 Patient demographics and baseline characteristics
IFN β-1b
group
N = 303
Other DMTs
group
N = 21
Total
N = 324
Age (years)
Mean 41.5 ± 11.29 44.9 ± 11.15 41.8 ± 11.30
Median (min–max) 40.0
(19.0–68.0)
43.0
(24.0–68.0)
40.0
(19.0–68.0)
Women, n (%) 207 (68.3) 14 (66.7) 221 (68.2)
Subtype of MS, n (%)
CIS 7 (2.3) 0 (0.0) 7 (2.2)
RRMS 286 (94.4) 19 (90.5) 305 (94.1)
SPMS 10 (3.3) 2 (9.5) 12 (3.7)
MS disease history
Duration since MS diagnosis (years)
Mean 6.7 ± 6.36 9.5 ± 9.16 6.9 ± 6.59
Median (min–max) 4.6 (0.2–35.0) 7.5 (0.3–43.4) 4.8
(0.2–43.4)
Presence of exacerbations,
n (%)
120 (39.6) 13 (61.9) 133 (41.0)
Number of exacerbations
Mean 1.5 ± 0.74 1.9 ± 1.14 1.6 ± 0.79
Median (min–max) 1.0 (0.0–5.0) 2.0 (1.0–5.0) 1.0 (0.0–5.0)
Reasons for switching to
ExtaviPro™, n (%)
Clinical reasonsa
Availability of new
auto-injector (patient
already treated with
Extavia®)
296 (97.7) 2 (9.5) 298 (92.0)
Lack/loss of effectiveness
of current treatment, as
evidenced by
returning/worsening/
progressing MS symptoms
2 (0.7) 6 (28.6) 8 (2.5)
Increasing frequency
of relapses/symptomatic
phases
2 (0.7) 3 (14.3) 5 (1.5)
MRI evaluation 3 (1.0) 6 (28.6) 9 (2.8)
Other 5 (1.7) 1 (4.8) 6 (1.9)
Poor tolerance 9 (3.0) 7 (33.3) 16 (4.9)
Patient-centred reasons
Compliance problem 19 (6.3) 9 (42.9) 28 (8.6)
Patient unable to
consistently store current
therapy under special
conditions
5 (1.7) 2 (9.5) 7 (2.2)
Data are presented as mean ± SD, unless stated otherwise
aMultiresponse option
CIS clinically isolated syndrome, DMT disease-modifying treatment, IFN
interferon, max maximum, min minimum, MRI magnetic resonance imaging,
MS multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, SD standard
deviation, SPMS secondary progressive multiple sclerosis
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the IFN β-1b (Extavia®) group, 12.2% of patients had car-
diovascular and/or metabolic comorbidities, 9.6% had
other neurological disorders, 6.6% had other auto-
immune disorders and 4.6% had other inflammatory dis-
orders or osteoporosis.
At baseline, the majority of patients (94.8%, n = 307)
were on IFN β-1b (Extavia®). Before switching to Extavi-
Pro™, 93.5% were using ExtaviJect® auto-injector, 3.4%
Avonex® Pen and remaining were on Betaject® Light/
Betaject® Lite, Betaject®/Betaject® Comfort/Betacomfort®,
Copaxone® autoject 2 or Rebiject II®. The main reasons
for switching to ExtaviPro™ auto-injector in the Extavia®
group were availability of new injector (97.7%), compli-
ance problems (6.3%) and poor tolerance (3.0%). In the
other DMT group, switches were initiated because of
compliance problems (42.9%), poor tolerance (33.3%),
loss of treatment effectiveness/evidenced by worsening
MS symptoms (28.6%), MRI evaluation (28.6%) and
increased frequency of relapses/symptomatic phases
(14.3%) (Table 1).
Patient satisfaction with ExtaviPro™
Of the 324 included patients, 290 had completed the
visit at Week 26. At baseline, 323 patient-reported
questionnaires were available and 282 at Week 26. At
Week 26, the overall mean ± SD patient satisfaction
score on the TSQM scale increased significantly to
75.6 ± 16.46 from baseline (73.0 ± 17.14; p = 0.0342,
Fig. 1). Patient satisfaction scores on TSQM subscales
for effectiveness, side effects and convenience
domains at Week 26 were 75.0 ± 18.65 (baseline,
71.6 ± 19.45; p = 0.0356), 88.5 ± 18.98 (baseline,
82.7 ± 22.93; p = 0.0002) and 77.6 ± 16.72 (baseline,
71.1 ± 17.53; p < 0.0001), respectively.
Tolerability of ExtaviPro™
Pain
Tolerability for pain with ExtaviPro™ was assessed
using SF-MPQ scores. The mean overall score for
total pain of 2.5 ± 4.56 units at Week 26 showed no
significant improvement versus baseline (3.3 ± 5.37;
p = 0.1103) on SF-MPQ.
At Week 26, mean sensory and affective items scores
on SF-MPQ were 1.7 ± 3.50 units (baseline 2.3 ± 4.08;
p = 0.1217) and 0.8 ± 1.46 units (1.0 ± 1.64; p = 0.1017),
respectively. The mean VAS score of 1.1 ± 1.92 units at
Week 26 was not improved significantly versus baseline
(1.3 ± 2.03; p = 0.3428).
The overall intensity of total pain experience at Week
26 (0.5 ± 0.84) showed no statistically significant improve-
ment versus baseline (0.5 ± 0.87; p = 0.6573).
Injection-site reactions
Patient responses to injection-site reactions are pre-
sented in Fig. 2. The frequency of injection-site reactions
and discomfort at the injection site versus baseline re-
ported as ‘about the same’ decreased by approximately
10% during the study period.
At Week 26, the percentage of patients experiencing
less frequent injection-site reactions (combined ‘much
less often’ or ‘somewhat less often’) was significantly
higher than at baseline (54.3% versus 40.4%;
p = 0.0006). A significantly higher percentage of
patients felt less discomfort due to injection-site reac-
tions at Week 26 (54.3% for combined ‘much less
discomfort’ or ‘somewhat less discomfort’) versus
baseline (40.4%; p = 0.0003).
Responses for incidence of injection-site reactions re-
ported by patients in the MSTCQ questionnaire were in
general but not always comparable to responses pro-
vided by physicians.
Adherence to ExtaviPro™
Compared with baseline, a statistically significant im-
provement was observed for the barriers to adherence
score of 4.2 (p = 0.0359) and the side-effects score of
4.6 (p = 0.0006) at Week 26 on the MSTAQ
subscales. Scores in the MSTAQ questionnaire for
coping strategies did not change significantly at Week
26 (Fig. 3).
Treatment compliance was achieved when patients
had taken at least 80% of medications prescribed at the
baseline visit. The percentage of patients who missed an
injection during the study period ranged between 13.2%
and 22.6%. No statistically significant difference was
observed between each study visit versus baseline. At
Week 26, a high treatment compliance of at least 96%
was reached.
Fig. 1 Mean TSQM scores for patient satisfaction at baseline and
Week 26. *p < 0.05; **p = 0.0002; ***p < 0.0001. TSQM, Treatment
Satisfaction Questionnaire for Medication
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Nurses’ acceptance for ExtaviPro™
Nurses reported that 94.8% patients found learning to
use ExtaviPro™ ‘easy’ or ‘very easy’. They also ex-
pected that for the majority (>95%) of patients, future
use of the auto-injector would be ‘easy’ or ‘very easy’.
The nurses also reported a high level of acceptance of
ExtaviPro™ during the study and that the need for
additional training to use the device was reduced with
time; 98.6% patients needed no additional training to
use the new auto-injector at Week 26. Overall, nurses
reported that 95.0–97.8% patients felt that the use of
the device was ‘easy’ or ‘very easy’.
Adverse events
Of all reported AEs (n = 91), the most frequently re-
ported AEs were headache (34.1%), MS relapse (7.7%),
depression (4.4%) and back pain (3.3%); remaining AEs
were singular in nature (~1%).
In total, six SAEs were reported, namely hospitalisa-
tion due to mild infection, mild neurological decom-
pensation, hospitalisation due to severe vertebroplasty,
hospitalisation due to an MS relapse, hospitalisation
due to cholecystectomy and death after a cerebral
haemorrhage. None of these events were suspected to
be related to the study and five of the patients recov-
ered completely. Two women discontinued the treat-
ment due to report of pregnancy during the study.
Discussion
This non-interventional European study evaluated ‘real-
world’ patient-reported outcomes and nurse satisfaction
with ExtaviPro™, a newly introduced auto-injector to de-
liver IFN β-1b (Extavia®) in day-to-day treatment of MS.
Injection-site reactions, pain and other side-effects (such
as flu-like symptoms) are common treatment challenges as-
sociated with the long-term use of subcutaneous IFN β-1b
[11, 12]. This can lead to decreased treatment compliance/
adherence in patients with MS [13, 14]. Previous studies
have reported that the use of auto-injectors has facilitated
self-administration and improved patient compliance to the
treatment [17, 18]. ExtaviPro™, an auto-injector featured to
have an ergonomic design, single-handed use, an ultra-thin
30G needle and easy access to difficult-to-reach injection
sites to reduce injection-site pain on administration of
high-dose and high-frequency subcutaneous IFN β-1b.
Responses at baseline were reported based on patients’ experience with prior injectors (4 weeks before entering into the study). 
Fig. 2 Proportion of patients experiencing injection-site reactions at baseline and Week 26. Responses at baseline were reported based on patients’ ex-
perience with prior injectors (4 weeks before entering into the study)
Fig. 3 Mean MSTAQ scores for patient treatment adherence at baseline
and Week 26. *p < 0.05; **p = 0.0006. DMT, disease-modifying therapy;
MSTAQ, Multiple Sclerosis Treatment Adherence Questionnaire
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The patient population in this real-world study included
twice as many women as men, with a mean age of approxi-
mately 42 years; approximately 94% had RRMS at baseline,
which is in line with previously published results on char-
acteristics of MS patients [27, 28]. The majority of patients
in this study were already using ExtaviJect® injector (93.5%)
for IFN-β1b (Extavia®) administration and the reason for
transitioning to the new ExtaviPro™ auto-injector was the
availability of the new auto-injector (97.7% patients).
The study evaluated patient satisfaction using the
TSQM which is designed to measure treatment satisfac-
tion in chronic diseases [20]. In the recently published
TENERE study by Vermersch et al. showed that the
TSQM is a useful tool and able to measure psychometric
properties in patients with RRMS [29]. In the present
study, the overall patient satisfaction score with IFN-β1b
(Extavia®) was increased significantly at Week 26.
Further, effectiveness, side effects and convenience on
the TSQM subscales were also improved significantly.
Patient satisfaction for the convenience subscale corrob-
orated with the preference reported in a previous survey
[19] in which convenience was rated as an important
general attribute for auto-injectors, and patients were
more likely to prefer ExtaviPro™ 30G over Betacomfort®
auto-injector for routine self-administration of IFN β-1b
[19]. Furthermore, the results were in line with the
non-interventional EXCELLENT study in which the con-
venience score with ExtaviJect™ increased significantly
between Weeks 6 and 12 on the TSQM subscale [30].
This finding suggests that ExtaviPro™ improved patient
treatment experience and satisfaction, particularly in
these subscales, and reflects the reliability associated
with the use of ExtaviPro™ 30G in MS patients.
In the present study, no significant changes in overall total
pain scores, affective items scores, sensory items scores, VAS
scores or overall intensity of total pain experience as assessed
on the SF-MPQ between baseline and Week 26 were ob-
served. Previous studies reported that the injection-site pain
is mainly associated with the needle diameter, and it has been
shown that with the use of a thinner needle such as 29G/
30G versus 27G, a significantly higher proportion of patients
were free from pain throughout the study as assessed
on the VAS [15, 31]. In the present study, 93.5% pa-
tients were using ExtaviJect® before switching to Exta-
viPro™, and the needle size of both the auto-injectors
was thin (30G). This could partly explain the lack of
a clinically meaningful change in pain scores from
baseline to Week 26 as assessed on the SF-MPQ.
No specific questionnaire is available to report responses
for injection-site reactions. We adapted the questions from
the MSTCQ tool to measure patient satisfaction with injec-
tion devices [15]. A considerable percentage of patients
(~54%) experienced a lower frequency of injection-site re-
actions and discomfort due to injection-site reactions at
Week 26. This corresponds with the findings reported in a
previous study by Mikol and colleagues, in which patients
reported significantly lesser injection-site reactions with the
auto-injector versus manual injectors (66.1% versus 71.8%;
p < 0.001) [16].
In the current study, patients reported their experience
within 4 weeks, suggesting an improvement using the new
auto-injector compared with the previous one. Frequency
and discomfort due to injection-site reactions with
ExtaviPro™ changed considerably during the study period,
reflecting an improvement compared with baseline. Fewer
injection-site reactions and discomfort or pain due to
injection-site reactions further explains a significant in-
crease in patient satisfaction with ExtaviPro™ 30G on the
TSQM subscale for the side-effect subscale.
Adherence to MS therapy as assessed by the MSTAQ
did not change significantly between any of the visits with
regard to coping strategies. Barriers to adherence and
side-effects scores were improved significantly at Week 26
from baseline, suggesting an improvement in patient com-
pliance and fewer side-effects versus baseline. Throughout
the study period, a high treatment compliance of at least
96% at all visits was achieved but without statistically sig-
nificant changes between baseline and Week 26.
Both nurses and patients agreed that ExtaviPro™ was easy
to use. Nurses reported that the use of the device had been
‘easy’ or ‘very easy’ to learn and to use for the first time. This
result was in line with an earlier international nurse survey
in which both patients and nurses perceived that ExtaviPro™
was easy to use and handle [32]. At Week 26, <2% of pa-
tients required additional training to use the device, reflect-
ing the user-friendly features of the device. During the
study, <5% of patients called or visited a nurse and/or a
physician due to concerns related to the use of ExtaviPro™.
No new safety signals were identified during the study.
The incidence of the most frequently reported
AEs—headache— was 34.1%. None of the six SAEs were
suspected to be related to the investigational product.
Safety of IFN β-1b administered using ExtaviPro™ was in
line with the known safety profile of IFN as reported in
earlier studies [7–10].
The study was designed originally to compare the
two groups, Extavia® and other DMTs (enrolment in a
1:1 ratio); however, due to the non-interventional na-
ture of the study, only 6.5% of patients were enrolled
in the other DMTs group and results were reported
using subject-own-control method. Thus, a compari-
son between the groups and conclusions on the
significance of any differences was not possible. Be-
cause it was a patient-reported outcome study, a
response-recall bias could have occurred as patients
would have become familiarised with the questions
and study objective over 26 weeks and tended to re-
spond favourably each time.
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Conclusion
In conclusion, this real-world study suggests that ad-
ministering IFN β-1b through the new ExtaviPro™
auto-injector significantly improves overall patient
satisfaction, including satisfaction associated with
side-effects, effectiveness and convenience on the
TSQM subscales in MS patients. ExtaviPro™ was easy
to use, contributed to patient satisfaction and was
well tolerated, which may support better adherence to
the treatment.
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